DK164700B - 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider eller -1,1-dioxider - Google Patents
3,4-disubstituerede 1,2,5-thiadiazol-1-oxider eller -1,1-dioxider Download PDFInfo
- Publication number
- DK164700B DK164700B DK269090A DK269090A DK164700B DK 164700 B DK164700 B DK 164700B DK 269090 A DK269090 A DK 269090A DK 269090 A DK269090 A DK 269090A DK 164700 B DK164700 B DK 164700B
- Authority
- DK
- Denmark
- Prior art keywords
- alkyl
- amino
- phenyl
- alkoxy
- hydroxy
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 75
- -1 3,4-disubstituted 1,2,5-thiadiazole-1-oxide Chemical class 0.000 claims description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000003282 alkyl amino group Chemical group 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 239000001301 oxygen Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 3
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical group S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 claims description 3
- 150000001204 N-oxides Chemical class 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 3
- 125000001589 carboacyl group Chemical group 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000001425 triazolyl group Chemical group 0.000 claims description 3
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- NPDLYUOYAGBHFB-WDSKDSINSA-N Asn-Arg Chemical group NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NPDLYUOYAGBHFB-WDSKDSINSA-N 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- WOEGVOXZZQORSZ-UHFFFAOYSA-N 2-[[4-(methylamino)-1-oxo-1,2,5-thiadiazol-3-yl]amino]ethanethiol Chemical compound CNC1=NS(=O)N=C1NCCS WOEGVOXZZQORSZ-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- BQRQOLQFLNSWNV-UHFFFAOYSA-N [5-[(dimethylamino)methyl]furan-2-yl]methanol Chemical compound CN(C)CC1=CC=C(CO)O1 BQRQOLQFLNSWNV-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- MFVQUHPQJXOZBZ-UHFFFAOYSA-N 2-[[4-(methylamino)-1,1-dioxo-1,2,5-thiadiazol-3-yl]amino]ethanethiol Chemical compound CNC1=NS(=O)(=O)N=C1NCCS MFVQUHPQJXOZBZ-UHFFFAOYSA-N 0.000 description 1
- ZRSLQBDTGLCFJJ-UHFFFAOYSA-N 3,4-dimethoxy-1,2,5-thiadiazole 1,1-dioxide Chemical compound COC1=NS(=O)(=O)N=C1OC ZRSLQBDTGLCFJJ-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- VKEQBMCRQDSRET-UHFFFAOYSA-N Methylone Chemical compound CNC(C)C(=O)C1=CC=C2OCOC2=C1 VKEQBMCRQDSRET-UHFFFAOYSA-N 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N dimethylacetone Natural products CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- MJEMIOXXNCZZFK-UHFFFAOYSA-N ethylone Chemical compound CCNC(C)C(=O)C1=CC=C2OCOC2=C1 MJEMIOXXNCZZFK-UHFFFAOYSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 102220254284 rs755928199 Human genes 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Lubricants (AREA)
Description
i
DK 164700 B
Den foreliggende opfindelse angår hidtil ukendte 3,4-disubstitue-rede 1,2,5-thiadiazol-1-oxider eller -1,1-dioxider, der er nyttige som mellemprodukter ved fremstillingen af de i dansk patentansøgning nr.
3718/80 (svarende til fremlæggelsesskrift nr. 160.611 B) omhandlede 5 histamin ^-antagonister.
Disse histamin Hg-antagonister, som er nyttige til behandling af sygdommen peptisk ulcer, har formlen (O) p 10 ^s\
N N
M1 ‘ A-(CH2)raZ(CH2)nNH R1 hvori 15 p betegner 1 eller 2, 1 2 3 R betegner hydroxy eller NR R , 2 3 R og R hver især uafhængigt af hinanden betegner hydrogen, (lavere)al kyl, (lavere)alkenyl, (lavere)alkynyl, cyclo(1avere)-alkyl, cyclo(lavere)alkyl(lavere)alkyl, hydroxy(lavere)al kyl, (lavere)-20 alkoxy(lavere)al kyl, (lavere)alkylthio(lavere)alkyl, amino(lavere)al kyl, (lavere)al kyl amino(lavere)al kyl, di(lavere)al kyl amino(lavere)al kyl, pyrroli di no(1avere)alky1, p i peri d i no(1avere)al kyl, morpholi no(1avere)-alkyl, piperazino(lavere)alkyl, pyridyl(lavere)al kyl, amino, (lavere)-alkylamino, di(lavere)al kyl amino, 2,2,2-trifluorethyl, 2-fluorethyl, 25 hydroxy, (lavere)alkoxy, 2,3-dihydroxypropyl, cyano, cyano(lavere)-alkyl, amidino, (lavere)alkylamidino, A'-iCfy^Z'(CH2)n/-, phenyl, phenyl(lavere)al kyl, substitueret phenyl eller substitueret phenyl -(lavere)al kyl, hvori phenylringen kan indeholde en eller to substi-tuenter uafhængigt valgt blandt (1avere)al kyl, hydroxy, (lavere)-30 alkoxy og halogen eller en substituent valgt blandt methyl endioxy, 2
trifluormethyl og di(lavere)alkylamino, under den forudsætning at R
3 og R ikke begge er cyclo(lavere)al kyl, phenyl, substitueret phenyl, amino, (lavere)alkyl amino, di(lavere)alkylamino, hydroxy, (lavere)-alkoxy, cyano, amidino, (lavere) al kyl amid i no eller A'-iCHg)^ 35 Z'(CH2)n,-, eller R2 og R3 betegner tilsammen -CHgCHgXiCHg)^, r er et helt tal fra 1 til 3, inklusive, 4 X betegner methylen, svovl, oxygen eller N-R under den forudsætning, at når r er 1, er X methylen,
DK 164700B
2 4 R betegner hydrogen, (lavere)al kyl, (lavere)alkenyl, (lavere)-alkynyl, (lavere)alkanoyl eller benzoyl, m og m' er hver især uafhængigt af hinanden et helt tal fra O til 2, inklusive, 5 n og n' er hver især uafhængigt af hinanden et helt tal fra 2 til 4, inklusive, Z og V er hver især uafhængigt af hinanden svovl, oxygen eller methyl en, A og A' er hver især uafhængigt af hinanden phenyl, imidazolyl, 10 thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazo-lyl, oxadiazolyl, furyl, thienyl eller pyridyl, under den forudsætning at A og A' uafhængigt af hinanden kan indeholde en eller to substi-tuenter, idet den første substituent er udvalgt blandt (lavere)alkyl, hydroxy, trifluormethyl, halogen, amino, hydroxymethyl, (lavere)-15 alkoxy, -(CH2)qN=C og -(CH2)qNR5R6 20 og den anden er udvalgt blandt (lavere)al kyl, hydroxy, trifluormethyl, halogen, amino, hydroxymethyl og (lavere)alkoxy, q er et helt tal fra 0 til 6, inklusive, begge R er uafhængigt af hinanden som ovenfor defineret, eller de to R4-grupper kan tilsammen 25 betegne ethylen, og 5 6 R og R betegner hver især uafhængigt af hinanden hydrogen, (lavere) - alkyl, (lavere) al kenyl, (lavere) al kynyl, cycl o (lavere) al kyl eller phenyl, under den forudsætning at R og R ikke begge kan være 5 6 cyclo(lavere)al kyl eller phenyl, eller R og R kan sammen med det 30 nitrogenatom, hvortil de er knyttet, betegne pyrrolidino, morpholino, piperidino, methyl piperidino, N-methylpiperazino eller homopiperidino, eller et ikke-toxisk, farmaceutisk acceptabelt salt, hydrat, solvat eller N-oxid deraf.
De 3,4-disubstituerede 1,2,5-thiadiazol-l-oxider og -1,1-dioxider 35 ifølge opfindelsen har den almene formel (XVII) 3
DK 164700 B
(0)P
N N XVII
M
5 HS(CH2)nH/ NR2R3 hvori p er 1 eller 2, n er et helt tal fra 2 til 4, inklusive, 2 3 10 R og R hver især uafhængigt af hinanden betegner hydrogen, (lavere)- alkyl, (lavere)alkenyl, (lavere)alkynyl, cyclo(lavere)al kyl, cyclo- (lavere)alkyl(lavere)alkyl, hydroxy(lavere)al kyl, (lavere)alkoxy- (1avere)alky1, (1 avere)al kylth i o(1avere)al kyl, ami no(1avere)al kyl, (1avere)al kyl ami no(1avere)al kyl, di(1avere)al kyl ami no(1avere)al kyl, 15 pyrrolidino(lavere)alkyl, piperidino(lavere)alkyl, morpholino(lavere)- alkyl, piperazino(lavere)alkyl, pyridyl(lavere)al kyl, amino, (lavere)- alkyl amino, di(lavere)al kyl ami no, 2,2,2-tri fluorethyl, 2-fluorethyl, hydroxy, (lavere)alkoxy, 2,3-dihydroxypropyl, cyano, cyano(lavere)al kyl, amidino, (lavere)alkylamidino, A'-tCHgJ^Z'(CH2)n/-, phenyl, phenyl- 20 (lavere)al kyl, substitueret phenyl eller substitueret phenyl(lavere)- alkyl, hvori phenylringen kan indeholde én eller to substituenter uafhængigt udvalgt blandt (lavere)alkyl, hydroxy, (lavere)alkoxy og halogen, eller én substituent udvalgt blandt methyl endioxy, trifluor- 2 3 methyl og di(lavere)alkylamino, under den forudsætning at R og R ikke 25 begge kan være cyclo(lavere)al kyl, phenyl, substitueret phenyl, amino, (lavere)alkyl amino, di(lavere)al kyl amino, hydroxy, (lavere)alkoxy, cyano, amidino, (lavere)alkylamidino eller A'-(CH2)m,Z'(CH2)n/-> eller R^ og R3 kan tilsammen betegne -CHgCHgXiCHjJp-, r er et helt tal fra 1 til 3, inklusive, 4 30 X betegner methylen, svovl, oxygen eller N-R , under den forudsætning, at når r er 1, betegner X methylen, R* betegner hydrogen, (1avere)al kyl, (1avere)alkenyl, (1avere)alkynyl, (lavere)alkanoyl eller benzoyl, m' er et helt tal fra 0 til 2, inklusive, 35 n' er et helt tal fra 2 til 4, inklusive, 1' betegner svovl, oxygen eller methylen, A' betegner phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, iso-xazolyl, triazolyl, thi adi azolyl, oxadiazolyl, furyl, thienyl eller
DK 164700 B
4 pyridyl, under den forudsætning at A' kan indeholde en eller to substi-tuenter, idet den første substituent er udvalgt blandt (lavere)alkyl, · hydroxy, trifluormethyl, halogen, amino, hydroxymethyl, (lavere)alkoxy, 5 NHR4 -(CH2>qN=CC^ °9 -(CH2)qNR5R6 NHR4 og den anden er udvalgt blandt (lavere)alkyl, hydroxy, trifluormethyl, 10 halogen, amino, hydroxymethyl og (lavere)alkoxy, q er et helt tal fra O til 6, inklusive, 4 hvert R er uafhængigt af hinanden som ovenfor defineret, eller de to 4 R -grupper kan tilsammen betegne ethyl en, og 5 6 R og R betegner hver især uafhængigt af hinanden hydrogen, (lavere)- 15 al kyl, (lavere) alkenyl, (lavere)alkynyl, cyclo(lavere)alkyl eller 5 6 phenyl, under den forudsætning at R og R ikke begge kan være cyclo- 5 6 (lavere)al kyl eller phenyl, eller R og R kan sammen med det nitrogenatom, hvortil de er knyttet, betegne pyrrolidino, morpholino, piperi-dino, methyl piperidino, N-methylpiperazino eller homopiperidino, 20 eller et salt, hydrat, solvat eller N-oxid deraf.
Forbindelserne med formlen I kan fremstilles ud fra en forbindelse med formlen XVII via den i reaktionsskemaet nedenfor anførte reaktionsvej.
Omsætningerne udføres i et inert organisk opløsningsmiddel. Det har 25 vist sig, at methanol er et hensigtsmæssigt og let tilgængeligt opløsningsmiddel. Reaktionstemperaturen er ikke kritisk. De fleste udgangsmaterialer er temmelig reaktive, og det foretrækkes at udføre omsætningen ved en temperatur under stuetemperatur, f.eks. 0-10°. Med nogle mindre reaktive forbindelser er det hensigtsmæssigt at udføre 30 omsætningen ved stuetemperatur. Undertiden er det ønskeligt senere at hæve reaktionsblandingens temperatur (f.eks. til 50-60°) for at fuldende omsætningen.
5
DK 164700 B
(O) p /sv
Reaktionsskema „ x ---- N n M, R7 R7
II
/R10H \^S(CH2)nHH2 (0)p (0)p
NN N N
W // \\J
R7 R10 HS(CH2)n!IH R7 χ„ XI11 \ / \hS(CH_) NH- / \ 2 n 2 /r10h (0) /s\
N N
\\ // ^
1 / ^ R10 HS(CH2)nNH K
A(CH2)mX
V
(0)p /S\ K.
A(CH-) S(CH-) NH R
λ m i n I c 6
DK 164700 B
I reaktionsskemaet betegner en let fraspaltelig gruppe udvalgt blandt halogen, (lavere)alkoxy, (lavere)alkylthio, phenoxy eller phenylthio, som kan indeholde 1 eller 2 substituenter udvalgt blandt 10 2 3 halogen, (lavere)al kyl, (lavere)alkoxy og nitro, R -NR R , og X er en 5 konventionel fraspaltelig gruppe. Egnede fraspaltelige grupper omfatter f.eks. fluor, chlor, brom, iod, -O^SR^, hvori R** betegner (lavere)-alkyl (f.eks. methansulfonat), aryl eller substitueret aryl (f.eks. benzensul fonat, p-brombenzensulfonat eller p-toluensul fonat), O^SF, acetoxy og 2,4-dinitrophenoxy. Af nemheds og økonomiske grunde fore-10 trækkes det at anvende en forbindelse, hvori X betegner chlor. Omsætningen af forbindelsen med formlen XVII med AiCHg)^ kan udføres i et hvilket som helst inert organisk opløsningsmiddel, såsom en alkanol, acetonitril, dimethyl formamid, dimethyl sulfoxid, acetone, og lignende.
Det foretrækkes at udføre omsætningen i en alkanol, såsom methanol, 15 ethanol eller isopropanol. Reaktionstemperaturen er ikke kritisk; omsætningen kan udføres ved temperaturer på fra ca. 0° til ca. 200°C. Ved lave temperaturer er omsætningen langsom, medens høje temperaturer normalt fører til mindre rene produkter på grund af nedbrydning og dannelse af biprodukter. Det foretrækkes sædvanligvis at udføre omsæt-20 ningen ved stuetemperatur. Omsætningen af forbindelsen med formlen XVII med AiCHgJrøX til dannelse af forbindelsen med formlen Ic udføres fortrinsvis i nærværelse af en base, som letter omsætningen ved at optræde som en syreacceptor. Egnede baser omfatter f.eks. NaOH, KOH, LiOH, triethylamin, dimethylanilin, natriumethoxid, og lignende. Hvor X 25 betegner hydroxyl, kan omsætningen udføres i koncentreret mineral syre, f.eks. HC1. Alle mellemprodukter med formlen XIII, XIV og XVII er hidtil ukendte forbindelser.
Eksempel 1 30 3-methyl ami no-4-(2-mercaptoethylami no)-1,2,5-th i adi azol-1,1-di oxi d Eh opløsning af 2-aminoethanthiol (fra hydrochloridet 1,91 g, 16,8 mmol) i 20 ml methanol sattes dråbevis i løbet af en periode på 15 minutter til en godt omrørt suspension af 3,4-dimethoxy-l,2,5--thiadiazol-l,l-dioxid (3,0 g, 16,8 mmol) i 250 ml methanol, der var 35 blevet afkølet til 1° i et is-vandbad. Efter 10 minutter ved 2-4° bob-ledes methylamin til den afkølede opløsning i 6 minutter, og omrøring fortsattes i yderligere 30 minutter ved omgivelsernes temperatur. Reaktionsblandingen inddampedes under formindsket tryk, og remanensen 7
DK 164700 B
anbragtes på 45 g silicagel og kromatograferedes under anvendelse af en gradienteluering af methylenchlorid-methanol. De relevante fraktioner forenedes og inddampedes, og produktet (2,43 g) krystalliseredes fra absolut ethanol. Omkrystallisation fra absolut ethanol gav titelfor-5 bindeisen, snip. 259-260° (dek.).
Analyse for C5Hjo^402S2:
Beregnet: C: 27,03, H: 4,54, N: 25,20,
Fundet: C: 27,13, H: 4,55, N: 24,86.
10 Eksempel 2 3-methylamino-4-(2-mercaptoethylamino)-1,2,5-thi adi azol-1-oxid
En opløsning af 2-aminoethanthiol (fra hydrochloridet, 2,04 g, 18,0 mmol) i 25 ml methanol sattes dråbevis i løbet af en periode på 30 minutter til en godt omrørt suspension af 3,4-dimethoxy-l,2,5-15 -thiadiazol-l-dioxid (2,92 g, 18,0 mmol) (fremstillet ifølge eksempel 4, trin A) i 150 ml methanol, der var blevet afkølet til 3° i et is--vandbad. Efter 10 minutter bobledes vandfri methylamin til opløsningen i 6 minutter, og omrøring fortsattes ved omgivelsernes temperatur i yderligere 20 minutter. Reaktionsblandingen inddampedes 20 under reduceret tryk, og remanensen anbragtes på 45 g silicagel og kromatograferedes under anvendelse af en gradienteluering af methy-lenchlorid-methanol. De relevante fraktioner forenedes og inddampedes til dannelse af 2,74 g af produktet. Omkrystallisation fra methanol og derpå 95% ethanol gav titel forbindel sen, smp. 191-193°.
25
Eksempler på fremstillingen af slutforbindelser med formlen (I) ud fra forbindelser ifølge opfindelsen.
Eksempel 3 30 3-(2-((5-dimethylaminomethyl-2-furyl)methylthio1ethylamino)-4-methylamino-l,2,5-thiadiazol-l,l-dioxid
En blanding indeholdende 3-methylamino-4-(2-mercaptoethylamino)- l,2,5-thiadiazol-l,l-dioxid (1,0 g, 4,5 mmol) (fremstillet i eksempel 1) og 5-dimethylaminomethyl-2-furanmethanol (0,82 g, 4,5 mmol) (fremstillet 35 i henhold til den i J. Chem. Soc., 4728 (1958) beskrevne fremgangsmåde) i 20 ml koncentreret saltsyre omrørtes i et is-vandbad i 2 timer og henstod derefter ved 0° i 64 timer. Reaktionsblandingen omrørtes ved omgivelsernes temperatur under reduceret tryk, og remanensen deltes 8
DK 164700 B
mellem vand og methylenchlorid. Den vandige fase gjordes basisk med natriumbicarbonat og ekstraheredes med methylenchlorid. Den forenede organiske fase vaskedes med mættet saltvandsopløsning, tørredes og inddampedes under reduceret tryk. Remanensen anbragtes på 25 g silicagel 5 og kromatograferedes under anvendelse af en gradieneluering af methylenchlorid-methanol. Den relevante fraktion inddampedes, og produktet krystalliseredes fra methanol. Omkrystallisation fra methanol gav titel forbindel sen, smp. 92-96°.
10 Eksempel 4 3-(2-Γ(5-dimethylaminomethyl-2-furyl)methyl hi olethyl amino)-4-methyl -amino-1,2,5-thiadiazol-l-oxid Når 3-methyl amino-4-(2-mercaptoethylamino)-1,2,5-thiadiazol-l-oxid (fremstillet i eksempel 2) behandles med ca. 1 ækvivalent 5-dimethyl ami-15 nomethyl-2-furanmethanol i koncentreret saltsyre i henhold til den i eksempel 3, beskrevne fremgangsmåde fås titel forbindel sen; identisk med produktet ifølge eksempel 13. Smp. 86-92°C.
Analyse for
Beregnet: C: 45,46, H: 6,16, H: 20,39, S: 18,67.
20 Fundet: C: 45,24, H: 6,24, N: 20,41, S, 18,90.
Claims (1)
- 9 DK 164700 B 1. 3,4-disubstitueret 1,2,5-thiadiazol-1-oxid eller -1,1-oxid med formlen 5 p /> H us(Oi2)nm nrV hvori p er 1 eller 2, n er et helt tal fra 2 til 4, inklusive, 2 3 R og R hver især uafhængigt af hinanden betegner hydrogen, (1avere)- 15 al kyl, (lavere)alkenyl, (lavere)alkynyl, cyclo(lavere)al kyl, cyclo- (lavere)alkyl(lavere)alkyl, hydroxy(lavere)alkyl, (lavere)alkoxy- (lavere)al kyl, (lavere)al kyl thio(lavere)al kyl, amino(lavere)al kyl, (lavere)al kyl amino(lavere)al kyl, di(lavere)alkylamino(lavere)alkyl, pyrrol i d i no(1avere)al kyl, p i peri di no(1avere)alky1, morpholi no(1avere)- 20 alkyl, piperazino(lavere)alkyl, pyridyl(lavere)al kyl, amino, (lavere)- alkylamino, di(lavere)al kyl amino, 2,2,2-trifluorethyl, 2-fluorethyl, hydroxy, (lavere)alkoxy, 2,3-dihydroxypropyl, cyano, cyano(lavere)al kyl, amidino, (lavere)al kyl amidi no, A/'(CH2)ni/Z,(CH2)n/-, phenyl, phenyl- (lavere)al kyl, substitueret phenyl eller substitueret phenyl(lavere)- 25 al kyl, hvori phenylringen kan indeholde én eller to substituenter uafhængigt udvalgt blandt (lavere)al kyl, hydroxy, (lavere)alkoxy og halogen, eller én substituent udvalgt blandt methyl endioxy, trifluor- 2 3 methyl og di(1averejalkyl amino, under den forudsætning at R og R ikke begge kan være cyclo(lavere)al kyl, phenyl, substitueret phenyl, amino, 30 (lavere)al kyl amino, di(lavere)al kyl ami no, hydroxy, (lavere)alkoxy, cyano, amidino, (lavere)alkylamidino eller A,-(CH2)m,Z/(CH2)n,-, eller R^ og R^ kan tilsammen betegne -CH2CH2X(CH2)r-, r er et helt tal fra 1 til 3, inklusive, X betegner methylen, svovl, oxygen eller N-R4, under den forudsætning, 35 at når r er 1, betegner X methylen, R4 betegner hydrogen, (1avere)al kyl, (1avere)alkenyl, (1avere)alkynyl, (lavere)alkanoyl eller benzoyl, m' er et helt tal fra 0 til 2, inklusive, 10 DK 164700 B n' er et helt tal fra 2 til 4, inklusive, V betegner svovl, oxygen eller methyl en, A' betegner phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, iso-xazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl eller 5 pyridyl, under den forudsætning at A' kan indeholde en eller to substi-tuenter, idet den første substituent er udvalgt blandt (lavere)alkyl, hydroxy, trifluormethyl, halogen, amino, hydroxymethyl, (lavere)alkoxy, ^—-NHR4 10 -(CH2^qN=CC^ °9 -(CH2)qNR5R6 NHR^ og den anden er udvalgt blandt (lavere)alkyl, hydroxy, trifluormethyl, halogen, amino, hydroxymethyl og (lavere)alkoxy, 15. er et helt tal fra O til 6, inklusive, hvert R er uafhængigt af hinanden som ovenfor defineret, eller de to 4 R -grupper kan tilsammen betegne ethyl en, og 5 6 R og R betegner hver især uafhængigt af hinanden hydrogen, (lavere)- alkyl, (lavere) alkenyl, (lavere) al kynyl, cycl o (lavere) al kyl eller 20 phenyl, under den forudsætning at R og R ikke begge kan være cyclo- 5 6 (lavere)alkyl eller phenyl, eller R og R kan sammen med det nitrogenatom, hvortil de er knyttet, betegne pyrrolidino, morpholino, piperi-dino, methyl piperidino, N-methylpiperazino eller homopiperidino, eller et salt, hydrat, sol vat eller N-oxid deraf. 25 30 35
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7251779A | 1979-09-04 | 1979-09-04 | |
US7251779 | 1979-09-04 | ||
US11718280A | 1980-01-31 | 1980-01-31 | |
US11718280 | 1980-01-31 | ||
US16383180A | 1980-06-07 | 1980-06-07 | |
US16383180 | 1980-06-07 |
Publications (4)
Publication Number | Publication Date |
---|---|
DK269090D0 DK269090D0 (da) | 1990-11-09 |
DK269090A DK269090A (da) | 1990-11-09 |
DK164700B true DK164700B (da) | 1992-08-03 |
DK164700C DK164700C (da) | 1992-12-21 |
Family
ID=27372107
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK371880A DK160611C (da) | 1979-09-04 | 1980-09-01 | Analogifremgangsmaade til fremstilling af 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider og -1,1-dioxider |
DK269190A DK164702C (da) | 1979-09-04 | 1990-11-09 | 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider eller -1,1-dioxider |
DK269090A DK164700C (da) | 1979-09-04 | 1990-11-09 | 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider eller -1,1-dioxider |
DK268990A DK164363C (da) | 1979-09-04 | 1990-11-09 | 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK371880A DK160611C (da) | 1979-09-04 | 1980-09-01 | Analogifremgangsmaade til fremstilling af 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider og -1,1-dioxider |
DK269190A DK164702C (da) | 1979-09-04 | 1990-11-09 | 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider eller -1,1-dioxider |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK268990A DK164363C (da) | 1979-09-04 | 1990-11-09 | 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider |
Country Status (23)
Country | Link |
---|---|
US (1) | US4374248A (da) |
AR (1) | AR240559A1 (da) |
AT (2) | AT376978B (da) |
CA (4) | CA1167841A (da) |
CH (2) | CH649764A5 (da) |
CS (1) | CS235951B2 (da) |
CY (2) | CY1360A (da) |
DE (2) | DE3033169C2 (da) |
DK (4) | DK160611C (da) |
FI (1) | FI76795C (da) |
GB (2) | GB2067987B (da) |
HK (2) | HK41387A (da) |
IE (2) | IE50997B1 (da) |
KE (2) | KE3685A (da) |
LU (1) | LU82753A1 (da) |
MY (2) | MY8700735A (da) |
NL (3) | NL189197C (da) |
NO (4) | NO160003C (da) |
NZ (1) | NZ194831A (da) |
PT (1) | PT71764B (da) |
SE (5) | SE449099B (da) |
SG (1) | SG61187G (da) |
ZW (1) | ZW20580A1 (da) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0040696B1 (en) * | 1980-04-30 | 1986-08-27 | Merck & Co. Inc. | Aminothiadiazoles as gastric secretion inhibitors |
US4904792A (en) * | 1980-10-02 | 1990-02-27 | Eli Lilly And Company | N-thiazolymethylthioalkyl-N'-alkylamidines and related compounds |
US4760075A (en) * | 1980-10-02 | 1988-07-26 | Eli Lilly And Company | N-thiazolylmethylthioalkyl-N-alkyl-amidines and related compounds |
US4471122A (en) * | 1981-03-03 | 1984-09-11 | Bristol-Myers Company | Thiadiazole histamine H2 -antagonists |
EP0065823A1 (en) * | 1981-05-13 | 1982-12-01 | Imperial Chemical Industries Plc | Heterocyclic guanidines as histamine H-2 antagonists |
IE53068B1 (en) * | 1981-06-15 | 1988-05-25 | Merck & Co Inc | Diamino isothiazole-1-oxides and -1,1-dioxides as gastic secretion inhibitors |
EP0073971B1 (en) * | 1981-08-24 | 1986-05-21 | Merck & Co. Inc. | Thiadiazole oxides as gastric antisecretory agents |
GR77847B (da) * | 1981-12-14 | 1984-09-25 | American Home Prod | |
US4528375A (en) * | 1982-03-29 | 1985-07-09 | Bristol-Myers Company | Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity |
US4528377A (en) * | 1982-03-29 | 1985-07-09 | Bristol-Myers Company | Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity |
US4578471A (en) * | 1982-03-29 | 1986-03-25 | Bristol-Myers Company | Substituted amino alkyl pyridyl ethanediimidamides |
ZA832154B (en) * | 1982-03-29 | 1983-12-28 | Bristol Myers Co | Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine h2-receptor antagonist activity |
US4517366A (en) * | 1982-03-29 | 1985-05-14 | Bristol-Myers Company | Intermediates for preparing 3,4-diamino-1,2,5-thiadiazoles |
US4528378A (en) * | 1982-03-29 | 1985-07-09 | Bristol-Myers Company | Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity |
FI832519L (fi) * | 1982-07-12 | 1984-01-13 | Bristol Myers Co | Farmaceutiska foerfaranden och sammansaettningar |
US4520025A (en) * | 1982-07-21 | 1985-05-28 | William H. Rorer, Inc. | Bicyclic nitrogen heterocyclic ethers and thioethers, and their pharmaceutical uses |
EP0105732A3 (en) * | 1982-10-01 | 1985-09-04 | Beecham Group Plc | Histamine h2 receptor antagonists of the benzisothiazole amino and benzthiadiazine amino series |
US4461900A (en) * | 1983-03-14 | 1984-07-24 | American Home Products Corporation | 4,5-Dihydrothiadiazole 1,1-dioxide derivatives |
US4440933A (en) * | 1983-03-16 | 1984-04-03 | Bristol-Myers Company | Process for preparing 1,2,5-thiadiazoles |
AT387384B (de) * | 1983-03-16 | 1989-01-10 | Bristol Myers Co | Verfahren zur herstellung von thiadiazolderivaten |
EP0123741A1 (en) * | 1983-04-26 | 1984-11-07 | Shionogi & Co., Ltd. | 2-Guanidino-4-hydroxymethylthiazole and derivatives thereof |
US4543352A (en) * | 1983-04-29 | 1985-09-24 | William H. Rorer, Inc. | Naphthalene aminoalkylene ethers and thioethers, and their pharmaceutical uses |
DE3326545A1 (de) * | 1983-07-22 | 1985-01-31 | Ludwig Heumann & Co GmbH, 8500 Nürnberg | Propan-2-ol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US4529731A (en) * | 1983-09-22 | 1985-07-16 | American Home Products Corporation | Thiadiazolediamine derivative with histamine H-2 receptor inhibiting properties |
US4644006A (en) * | 1984-06-22 | 1987-02-17 | Bristol-Myers Company | Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity |
US4692531A (en) * | 1984-06-22 | 1987-09-08 | Bristol-Myers Company | Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity |
US4612309A (en) * | 1984-10-23 | 1986-09-16 | William H. Rorer, Inc. | Antisecretory bicyclic benzo-oxy heterocyclic ethers and thioethers |
GB8501535D0 (en) * | 1985-01-22 | 1985-02-20 | Smith Kline French Lab | Chemical compounds |
US4728648A (en) * | 1985-02-09 | 1988-03-01 | Smith Kline & French Laboratories Limited | Histamine antagonist triadiazole derivatives, compositions, and method of use therefor |
GB8509276D0 (en) * | 1985-04-11 | 1985-05-15 | Smith Kline French Lab | Pyridine derivatives |
GB8510680D0 (en) * | 1985-04-26 | 1985-06-05 | Smith Kline French Lab | Pyridine derivatives |
CA1286297C (en) * | 1985-06-13 | 1991-07-16 | George S. Sach | Pyridine derivatives |
DE3532880A1 (de) * | 1985-09-14 | 1987-03-26 | Basf Ag | 1,4-disubstituierte pyrazolderivate |
GB8610867D0 (en) * | 1986-05-02 | 1986-06-11 | Smith Kline French Lab | 3-hydroxypyridines |
ES2008962A6 (es) * | 1987-12-17 | 1989-08-16 | Marga Investigacion | Proceso para la preparacion de nuevos compuestos de 2-guanidinotiazol |
EP0515121B1 (en) * | 1991-05-21 | 2000-11-02 | Eli Lilly And Company | Process for preparing intermediates to nizatidine and related compounds |
US5248673A (en) * | 1992-12-23 | 1993-09-28 | Bristol-Myers Squibb Co. | Bisamidine derivatives as thrombin inhibitors |
US5821371A (en) * | 1994-10-24 | 1998-10-13 | Eli Lilly And Comany | Heterocyclic compounds and their preparation and use |
US5618816A (en) * | 1995-03-02 | 1997-04-08 | Bristol-Myers Squibb Company | Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridnyl and pyrimidinylpiperazines |
US5767280A (en) * | 1995-06-01 | 1998-06-16 | Eli Lilly And Company | Process for making heterocyclic compounds |
AU2003288922A1 (en) | 2002-10-09 | 2004-05-04 | Pharmacopeia, Inc. | Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands |
MXPA06007076A (es) | 2003-12-19 | 2006-08-31 | Pharmacopeia Drug Discovery | Tiadiazoles como ligandos del receptor cxc y cc-quimiocina. |
US7671212B2 (en) | 2003-12-22 | 2010-03-02 | Schering Corporation | Isothiazole dioxides as CXC- and CC-chemokine receptor ligands |
CA2613607A1 (en) | 2005-06-29 | 2007-01-04 | Schering Corporation | Di-substituted oxadiazoles as cxc-chemokine receptor ligands |
DE602006017849D1 (de) | 2005-06-29 | 2010-12-09 | Schering Corp | 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc-chemokinrezeptors |
WO2013134562A1 (en) | 2012-03-09 | 2013-09-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
WO2014009293A1 (en) | 2012-07-13 | 2014-01-16 | Basf Se | New substituted thiadiazoles and their use as fungicides |
CA2894281C (en) | 2012-12-20 | 2021-04-20 | Inception 2, Inc. | Triazolone compounds and uses thereof |
PE20160880A1 (es) | 2013-09-06 | 2016-09-22 | Inception 2 Inc | Compuestos de triazolona y usos de los mismos |
CN105061360B (zh) * | 2015-07-28 | 2018-06-19 | 首都师范大学 | 一种3,4-二氨基-1,2,5-噻二唑的提纯方法 |
US20230349922A1 (en) | 2020-08-11 | 2023-11-02 | Université De Strasbourg | H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL22850A (en) * | 1964-03-18 | 1968-12-26 | Merck & Co Inc | 3-chloro-1,2,5-thiazdiazole-4-carboxylic acid being an intermediate in the preparation of sulfa drugs |
CH482712A (de) * | 1964-10-01 | 1969-12-15 | Merck & Co Inc | Verfahren zur Herstellung von 3-Amino-1,2,5-thiadiazolen |
US3564000A (en) * | 1965-10-15 | 1971-02-16 | Merck & Co Inc | Process for preparing 3-chloro-4-hydroxy-1,2,5-thiadiazole derivatives |
US3419573A (en) * | 1965-10-15 | 1968-12-31 | Merck & Co Inc | 3-chloro-4-oxy-1,2,5-thiadiazoles, and a process for preparing same |
DE1770152A1 (de) * | 1968-04-08 | 1971-09-30 | Lentia Gmbh | Verfahren zur Herstellung von 3-Amino-4-brom-1,2,5-thiadiazol |
US3657237A (en) * | 1968-05-22 | 1972-04-18 | Frosst & Co Charles E | Process for making 1 2 5-thiadiazoles in the sinister configuration |
US4104381A (en) * | 1973-05-03 | 1978-08-01 | Smith Kline & French Laboratories Limited | Pharmacologically active compounds |
AT348517B (de) * | 1977-01-19 | 1979-02-26 | Chemie Linz Ag | Verfahren zur herstellung von reinem 3-methoxy- 4- (4'-aminobenzolsulfonamido) -1,2,5-thiadiazol |
GR62452B (en) * | 1977-04-20 | 1979-04-12 | Ici Ltd | Preparation process of guanidine derivatives |
US4165378A (en) * | 1977-04-20 | 1979-08-21 | Ici Americas Inc. | Guanidine derivatives of imidazoles and thiazoles |
US4374836A (en) * | 1978-10-16 | 1983-02-22 | Imperial Chemical Industries Ltd. | Antisecretory heterocyclic derivatives, process for their manufacture and pharmaceutical compositions containing them |
EP0040696B1 (en) * | 1980-04-30 | 1986-08-27 | Merck & Co. Inc. | Aminothiadiazoles as gastric secretion inhibitors |
DE3168031D1 (en) * | 1980-07-30 | 1985-02-14 | Ici Plc | Guanidine derivatives |
EP0073971B1 (en) * | 1981-08-24 | 1986-05-21 | Merck & Co. Inc. | Thiadiazole oxides as gastric antisecretory agents |
-
1980
- 1980-09-01 NL NLAANVRAGE8004967,A patent/NL189197C/xx not_active IP Right Cessation
- 1980-09-01 FI FI802740A patent/FI76795C/fi not_active IP Right Cessation
- 1980-09-01 DK DK371880A patent/DK160611C/da not_active IP Right Cessation
- 1980-09-02 GB GB8028326A patent/GB2067987B/en not_active Expired
- 1980-09-02 CY CY136080A patent/CY1360A/xx unknown
- 1980-09-02 NO NO80802576A patent/NO160003C/no unknown
- 1980-09-03 SE SE8006148A patent/SE449099B/sv not_active IP Right Cessation
- 1980-09-03 DE DE3033169A patent/DE3033169C2/de not_active Expired
- 1980-09-03 PT PT71764A patent/PT71764B/pt not_active IP Right Cessation
- 1980-09-03 CA CA000359493A patent/CA1167841A/en not_active Expired
- 1980-09-03 NZ NZ194831A patent/NZ194831A/en unknown
- 1980-09-03 IE IE1851/80A patent/IE50997B1/en not_active IP Right Cessation
- 1980-09-03 IE IE1175/86A patent/IE51235B1/en not_active IP Right Cessation
- 1980-09-03 AT AT0443480A patent/AT376978B/de active
- 1980-09-03 DE DE3051146A patent/DE3051146C2/de not_active Expired - Fee Related
- 1980-09-04 CS CS816979A patent/CS235951B2/cs unknown
- 1980-09-04 ZW ZW205/80A patent/ZW20580A1/xx unknown
- 1980-09-04 CH CH6659/80A patent/CH649764A5/de not_active IP Right Cessation
- 1980-09-04 LU LU82753A patent/LU82753A1/fr unknown
- 1980-09-04 CH CH1760/85A patent/CH658055A5/de not_active IP Right Cessation
-
1981
- 1981-06-23 US US06/276,586 patent/US4374248A/en not_active Expired - Lifetime
-
1982
- 1982-11-02 CA CA000579080A patent/CA1263115A/en not_active Expired
- 1982-11-02 CA CA000579079A patent/CA1263114A/en not_active Expired
- 1982-11-02 CA CA000431960A patent/CA1248962A/en not_active Expired
-
1983
- 1983-07-13 GB GB08318949A patent/GB2132190B/en not_active Expired
- 1983-07-13 CY CY140283A patent/CY1402A/xx unknown
- 1983-11-29 AR AR29495183A patent/AR240559A1/es active
-
1984
- 1984-02-27 AT AT0064584A patent/AT377257B/de not_active IP Right Cessation
- 1984-06-08 SE SE8403107A patent/SE456580B/sv not_active IP Right Cessation
- 1984-06-08 SE SE8403111A patent/SE461733B/sv not_active IP Right Cessation
- 1984-06-08 SE SE8403108A patent/SE456582B/sv not_active IP Right Cessation
- 1984-06-08 SE SE8403109A patent/SE456581B/sv not_active IP Right Cessation
-
1986
- 1986-06-23 NO NO86862501A patent/NO162664C/no unknown
- 1986-12-23 KE KE3685A patent/KE3685A/xx unknown
-
1987
- 1987-04-06 NO NO87871421A patent/NO160781C/no unknown
- 1987-04-06 NO NO87871420A patent/NO161737C/no unknown
- 1987-05-28 HK HK413/87A patent/HK41387A/xx unknown
- 1987-07-20 KE KE3742A patent/KE3742A/xx unknown
- 1987-07-28 SG SG611/87A patent/SG61187G/en unknown
- 1987-12-03 HK HK891/87A patent/HK89187A/xx unknown
- 1987-12-31 MY MY1987735A patent/MY8700735A/xx unknown
- 1987-12-31 MY MY1987585A patent/MY8700585A/xx unknown
-
1990
- 1990-11-09 DK DK269190A patent/DK164702C/da not_active IP Right Cessation
- 1990-11-09 DK DK269090A patent/DK164700C/da not_active IP Right Cessation
- 1990-11-09 DK DK268990A patent/DK164363C/da not_active IP Right Cessation
-
1992
- 1992-07-09 NL NL9201236A patent/NL9201236A/nl not_active Application Discontinuation
- 1992-07-09 NL NL9201237A patent/NL9201237A/nl not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK164700B (da) | 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider eller -1,1-dioxider | |
AU2007234843B2 (en) | Inhibitors of histone deacetylase | |
US6420367B1 (en) | Pyrimidine derivatives exhibiting antitumor activity | |
SU671728A3 (ru) | Способ получени производных 1,2-бензизотиазолинона-3 или их кислотно-аддитивных солей | |
EP2084155A1 (en) | Thiazole derivatives as kinase inhibitors | |
CZ166498A3 (cs) | Způsob přípravy 2-chlorthiazolových sloučenin a jejich použití | |
US3417085A (en) | 3,1-benzothiazines and 3,1-benzoxazines | |
HU176881B (en) | Process for producing derivatives of urea | |
FR2480751A1 (fr) | 4,1-benzoxazepines et leur utilisation comme produits pharmaceutiques pour le systeme nerveux central | |
CA2289572A1 (en) | Novel hexahydro-1,4-diazepine derivatives or salts thereof | |
CA1312870C (en) | Alkanesulfonamides as antiglaucoma agents | |
SU900813A3 (ru) | Способ получени производных тиенопиридина | |
US4678855A (en) | Substituted benzenesulfonamides | |
CA2011834A1 (en) | Indole derivatives | |
NO833478L (no) | Tiatriazinderivater | |
NO163055B (no) | Fremgangsmaate til fremstilling av substituerte 3,4-diamino-1,2,5-tiadiazoler. | |
Arranz et al. | Synthesis and pharmacological evaluationof 2, 3-dihydro-3-oxo-4H-thieno [3, 4-e][1, 2, 4] thiadiazine 1, 1-dioxidesas voltage-dependent calcium channel blockers | |
Molina et al. | Synthesis of 1, 2, 4-triazole and 1, 3, 4-thiadiazole derivatives from methyl 2-methyldithiocarbazate and heterocumulenes | |
DD153838A5 (de) | Verfahren zur herstellung von 3,4-disubstituierten 1,2,5-thiadiazol-1-oxiden und-1,1-dioxiden | |
NZ206317A (en) | Acridanone derivatives and pharmaceutical compositions | |
NO153848B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive n-(arylthioalkyl)-n`-(aminoalkyl)-ureaderivater. | |
US4094870A (en) | 2-Substituted thio-1,4-benzodiazepine derivatives | |
JP4420606B2 (ja) | 6−アリール−4H−s−トリアゾロ[3,4−c]−チエノ[2,3−e]−1,4−ジアゼピンの調製方法 | |
Moss | Synthesis of Heterocycles Containing Nitrogen and Sulphur | |
NO162070B (no) | Analogifremgangsm te til fremstilling av terapeutisk aktive triazol(2,3-c) (1,3)benzodiazepiner. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A0 | Application filed | ||
PBP | Patent lapsed |